Mark Avigan
Impact in
- Pharmacology top 0.2%
- Drug-Induced Hepatotoxicity and Protection
- Pharmacogenetics and Drug Metabolism
- Hepatology top 2%
- Liver Diseases and Immunity
Papers in
- Pharmacology 27
- Drug-Induced Hepatotoxicity and Protection 24
- Pharmacogenetics and Drug Metabolism 9
- Epidemiology 23
- Liver Disease Diagnosis and Treatment 20
- Hepatitis B Virus Studies 4
- Co-authors
- David Levens (5 shared papers)Lanh Green (2 shared papers)Ann Corken Mackey (2 shared papers)Patricia A. Dinndorf (1 shared paper)Leonard S. Bazar (4 shared papers)Henry C. Krutzsch (2 shared papers)Takeshi Tomonaga (2 shared papers)Raúl J. Andrade (4 shared papers)
- Journals
- Drug Safety (12 papers)Hepatology (4 papers)Alimentary Pharmacology & Therapeutics (4 papers)Clinical Pharmacology & Therapeutics (3 papers)Journal of Biological Chemistry (3 papers)
- Partner nations
- United StatesUnited KingdomBelgium
In The Last Decade
Mark Avigan
73 papers receiving 3.6k citations
Mark Avigan's Hit Papers
Peers
Comparison fields: 5 of 123
- Pharmacology 917
- Hepatology 482
- Toxicology 91
- Epidemiology 771
- Oncology 551
Countries citing papers authored by Mark Avigan
This map shows the geographic impact of Mark Avigan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Avigan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Avigan more than expected).
Fields of papers citing papers by Mark Avigan
This network shows the impact of papers produced by Mark Avigan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Avigan. The network helps show where Mark Avigan may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Avigan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 76 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Case Definition and Phenotype Standardization in Drug-Induced Liver Injury Hit paper breakdown → | 2011 | 760 |
| 2 | 2007 | 394 | |
| 3 | 1994 | 294 | |
| 4 | 1993 | 205 | |
| 5 | 2018 | 160 | |
| 6 | 1990 | 125 | |
| 7 | 1986 | 113 | |
| 8 | 2011 | 101 | |
| 9 | 1988 | 95 | |
| 10 | 2008 | 92 | |
| 11 | 2008 | 88 | |
| 12 | 2016 | 87 | |
| 13 | 1973 | 73 | |
| 14 | 1995 | 65 | |
| 15 | 2007 | 63 | |
| 16 | 2010 | 61 | |
| 17 | 2008 | 43 | |
| 18 | Treatment of chronic delta hepatitis with recombinant human alpha interferon. | 1987 | 43 |
| 19 | 2009 | 42 | |
| 20 | 1998 | 40 |
About Mark Avigan
Mark Avigan is a scholar working on Pharmacology, Epidemiology, Hepatology, Molecular Biology and Genetics, having authored 76 papers that have together received 3.7k indexed citations. Recurring topics across this work include Drug-Induced Hepatotoxicity and Protection (24 papers), Liver Disease Diagnosis and Treatment (20 papers), Pharmacogenetics and Drug Metabolism (9 papers), Hepatitis C virus research (8 papers), Liver physiology and pathology (6 papers), Hepatitis B Virus Studies (4 papers), Adipose Tissue and Metabolism (4 papers) and Liver Diseases and Immunity (4 papers). The work is most often cited by research in Pharmacology (917 citations), Hepatology (482 citations), Toxicology (91 citations), Epidemiology (771 citations) and Oncology (551 citations). Mark Avigan has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include David Levens, Lanh Green, Ann Corken Mackey, Patricia A. Dinndorf, Leonard S. Bazar, Henry C. Krutzsch, Takeshi Tomonaga, Raúl J. Andrade, Einar S. Björnsson and Neil Kaplowitz. Their work appears in journals such as Drug Safety, Hepatology, Alimentary Pharmacology & Therapeutics, Clinical Pharmacology & Therapeutics and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.